BBP-398 + sotorasib

BBP-398 + sotorasib is an investigational combination therapy being studied for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. BBP-398 is a potent, orally available small molecule inhibitor of SHP2 (protein tyrosine phosphatase non-receptor type 11), which plays a key role in linking growth factor, cytokine, and integrin signaling to the downstream RAS/ERK MAPK pathway that regulates cellular proliferation and survival. Sotorasib (LUMAKRAS) is a small molecule inhibitor targeting KRAS G12C mutations. The rationale for combining these agents is to simultaneously inhibit SHP2-mediated signaling upstream and directly target mutant KRAS G12C, potentially overcoming resistance mechanisms and improving antitumor efficacy in cancers driven by this mutation. The combination has received FDA Fast Track designation for previously treated adults with locally advanced or metastatic KRAS G12C-mutated NSCLC[1][2][6][9].

Brand names

LUMAKRAS

Other names

BBP-398 + LUMAKRAS